Shape Therapeutics

Share on: 

ShapeTX is developing Gene Therapies using proprietary RNA technologies. The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfixTM, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVidTM, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs.

The company is currently working to develop gene therapies for Alzheimer’s and Parkinson’s disease.


Seattle WA
United States